Atara begins Phase III testing of tabelecleucel to treat EBV-PTLD

Atara Biotherapeutics Inc. (NASDAQ:ATRA) began two open-label, international Phase III trials of tabelecleucel to treat Rituxan rituximab-refractory Epstein-Barr

Read the full 188 word article

User Sign In